<DOC>
	<DOCNO>NCT01673711</DOCNO>
	<brief_summary>This clinical trial study deuterated phenanthrene tetraol smoker high risk lung cancer . Studying sample urine laboratory smoker high risk lung cancer may help doctor learn biomarkers related cancer .</brief_summary>
	<brief_title>Deuterated Phenanthrene Tetraol Smokers Who Are High Risk For Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine relationship urinary deuterated ( [ D10 ] ) phenanthrene tetraol ( PheT ) level , PheT : phenanthrols ( HOPhe ) ratio , presence bronchoepithelial metaplasia and/or dysplasia smoker undergo screen bronchoscopy Roswell Park Cancer Institute ( RPCI ) . OUTLINE : Patients receive deuterated phenanthrene tetraol orally ( PO ) . Urine sample collect laboratory study 6 hour dose .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<criteria>Current former smoker 18 year age old Documentation diagnosis dysplasia , dysplasia , metaplasia bronchoscopy ( white light and/or autofluorescence ) conduct less equal 10 year prior registration Not pregnant , plan become pregnant breastfeeding Able provide write informed consent indicate understanding nature study Willing comply study requirement , include take [ D10 ] phenanthrene water 20 % ethanol No previous history aerodigestive cancer Not currently undergo treatment cancer . Exception : basal cell squamous cell skin cancer Not currently take investigational agent No history allergic reaction [ D10 ] phenanthrene similar compound No major medical comorbidities , example , renal dysfunction , heart function , diabetes , adjudicate study physician Not former recover alcoholic No use metronidazole antabuse less equal 7 day prior [ D10 ] phenanthrene dosing , could potentially interact ethanol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>